PHASE-I STUDY OF 6-DIAZO-5-OXO-L-NORLEUCINE (DON)

Authors:
  • RSR B Sklaroff
    R B Sklaroff
  • ECE S Casper
    E S Casper
  • GMG B Magill
    G B Magill
  • CYC W Young
    C W Young

  • 1 January 1980
    • journal article
    • research article
    • Vol. 64  (12) , 1247-1251
    • PMID:7471114
Abstract
A phase I study of 6-diazo-5-oxo-L-norleucine given i.v. on a twice weekly schedule was conducted. Twenty-six evaluable [cancer] patients received 31 courses of the drug. Doses ranged from 100-500 mg/m2. Nausea with vomiting was the dose-limiting toxic effect, transient thrombocytopenia was seen frequently and mucositis occurred in 39% of the patients. No definite therapeutic responses were observed in 18 patients with measurable lesions. The recommended dose for phase II studies is 200-300 mg/m2 i.v. twice weekly.